Kalbe Farma KLBF IJ -Buy- Transforming the brand
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Consumer Durables SH JW SC 3.4K 28th Apr, 2025
Market share erosion persists
UNVR’s 1Q25 result was in line with our estimate (read: 1Q25F preview). In our view, UNVR still carries its main problem, i.e., weak demand creation, reflected in its -2.2% domestic sales CAGR for 2017-2024. In 1Q25, sales persistently declined by 6.6% y-y, dragged down by the home & personal care segment (HPC); however, on a q-q basis, sales were up by +21.6% due to seasonality and lower stock reduction at the distributor level, similar to the 4Q23-1Q24 period, when sales grew by +24.7% q-q (see Fig. 2). We expect the sluggish sales performance to continue due to external and internal factors. Externally, we have observed that local competitors have continuously improved and have become superior to UNVR in terms of distribution networks, pricing strategy, and brand positioning, which has caused UNVR to continuously lose market share. On top of that, internally, headquarters developed an inefficient chain of command structure, in our view, and has been continuously taking money through very high royalty rates for years, reflected in slow decision-making and a smaller budget to fight back against its competitors. However, we appreciate that the current CEO, Benjie Yap, has implemented a more radical approach to accelerate the stock reduction at the distributor level. However, after normalizing the stock level, the next and in our view bigger challenge would be demand creation to regain back market share amid increasing competition.
Maintain Reduce
In our view, UNVR will continue to underperform compared to peers, given its continuous market share decline. We project the company’s A&P-to-sales ratio will remain at a high level to defend market share. The divestment of its ice cream business could weaken UNVR’s bargaining power at the general trade (GT) level in the long run, in our view, despite the potential of a one-off dividend. All in all, we maintain our Reduce call for UNVR at a TP of IDR1,600, using a target FY25F P/E of 14.5x. Currently, the stock is trading at a FY25F P/E of 15.9x. Upside risks would be a consistent sales volume recovery; to achieve that, there are two minimum requirements, in our view: 1) streamlining distributors and strengthening distribution networks in GT; and 2) maintaining the current CEO for a longer time: any change in management would be a setback, in our view, as typically a new CEO needs two years to learn and fully implement their own strategy.
| UNVR IJ | QoQ | YoY | 3M25/ | 3M25/ | |||||||||||
| Profit and loss statement (IDRbn) | 1Q24 | 4Q24 | 1Q25 | (%) | (%) | Nmr | Cons. | ||||||||
| Revenue | 10,080 | 7,721 | 9,465 | 22.6 | (6.1) | 26.2 | 27.5 | ||||||||
| COGS | 5,047 | 4,282 | 4,906 | 14.6 | (2.8) | ||||||||||
| Gross profit | 5,033 | 3,439 | 4,559 | 32.6 | (9.4) | ||||||||||
| EBIT | 1,883 | 515 | 1,622 | 215.0 | (13.8) | 29.8 | 37.5 | ||||||||
| Other income/(expenses) | |||||||||||||||
| Net interest income/(expense) | (22) | (15) | (27) | (78.6) | (22.0) | ||||||||||
| Others | (1) | (13) | (1) | 94.1 | 4.4 | ||||||||||
| Pre-tax profit | 1,859 | 486 | 1,594 | 227.8 | (14.3) | ||||||||||
| Net profit | 1,449 | 359 | 1,237 | 244.7 | (14.6) | 29.5 | 32.0 | ||||||||
| Gross margin (%) | 49.9 | 44.5 | 48.2 | ||||||||||||
| EBIT margin (%) | 18.7 | 6.7 | 17.1 | ||||||||||||
| Pre-tax margin (%) | 18.4 | 6.3 | 16.8 | ||||||||||||
| Net margin (%) | 14.4 | 4.6 | 13.1 | ||||||||||||
| Balance sheet (IDRbn) | Mar-24 | Dec-24 | Mar-25 | ||||||||||||
| Cash and equivalents | 409 | 671 | 1,081 | ||||||||||||
| Total assets | 18,342 | 16,046 | 17,809 | ||||||||||||
| Total liabilities | 13,498 | 13,897 | 14,429 | ||||||||||||
| Interest bearing liabilities | 0 | 1,450 | 900 | ||||||||||||
| Equity | 4,844 | 2,149 | 3,380 | ||||||||||||
| ROA (%) | 31.6 | 8.9 | 27.8 | ||||||||||||
| ROE (%) | 119.6 | 66.8 | 146.4 | ||||||||||||
| Gearing (%) | 0.0 | 67.5 | 26.6 | ||||||||||||
| Net gearing (%) | n.c. | 36.2 | n.c. | ||||||||||||
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
| Rating Remains | Reduce |
| Target price Remains | IDR 1,600 |
| Closing price 25 April 2025 | IDR 1,750 |
Sandy Ham (sandy.ham@verdhana.id)
Jody Wijaya (jody.wijaya@verdhana.id)
Samuel Christian (samuel.christian@verdhana.id)
saya
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Based on our survey of distributors and wholesalers, MYOR's domestic sales may have grown
As mentioned in our previous reports, Indonesia local FMCG companies have
Our analysis of FMCG and retail sales data of companies we track across Indonesia suggests that Sulawesi,
AMRT has consistently outperformed its FMCG peers in terms of sales growth over the past decade
Indonesia is a young nation (110mn population are below 40yrs, based on BPS) as well as social media-savvy (th